Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Market Cap: US$13.3b

Neurocrine Biosciences Dividend

Dividend criteria checks 0/6

Neurocrine Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$2.48
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet

Mar 08
Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Dec 08
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Neurocrine initiated Equal Weight at Wells Fargo despite upcoming catalysts

Sep 26

Neurocrine to acquire U.K.-based biotech Diurnal

Aug 30

Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial

Aug 05

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Jul 26
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares

Jul 19

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NBIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NBIX's dividend payments have been increasing.


Dividend Yield vs Market

Neurocrine Biosciences Dividend Yield vs Market
How does NBIX dividend yield compare to the market?
SegmentDividend Yield
Company (NBIX)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.9%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (NBIX)0%

Notable Dividend: Unable to evaluate NBIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NBIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NBIX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NBIX has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.